$40,000 of TAKEDA PHARMACEUTICALS AMERICA INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, plasma therapy, and step therapy; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; H.R.830, HELP Copays Act; S.127, Pharmacy Benefit Manager Transparency Act of 2023; H.R.3285, Fairness for Patient Medications Act; S.1339, Pharmacy Benefit Manager Reform Act; H.R.5378, Lower Costs, More Transparency Act; S.3430, Better Mental Health Care Lower-Cost Drugs and Health Extenders Act; S.2973, Modernizing and Ensuring PBM Accountability Act; H.R.6283, DRUG Act; H.R.2630, Safe Step Act. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation; CMMI Proposed Accelerated Approval Payment Policy; CMMI Medicaid Proposed Rebate Rule. Issues related to federal health programs and prescription drugs; H.R.9027/S.4690, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2025; H.R.9029/S.4942, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025; H.R.10445, Further Continuing Appropriations and Disaster Relief Supplemental Appropriations Act, 2025; H.R.10545, American Relief Act, 2025. Issues related to tax reform. Tax issues related to H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169) implementation. Issues related to R&D tax credit; H.R.7024, Tax Relief for American Families and Workers Act of 2024. Issues related to orphan drug tax credit; H.R.5539/S.3131, ORPHAN Cures Act. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP and supply chain."
You can find more data on corporate lobbying on Quiver Quantitative.
TAK Hedge Fund Activity
We have seen 154 institutional investors add shares of TAK stock to their portfolio, and 114 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST TRUST ADVISORS LP added 3,178,214 shares (+inf%) to their portfolio in Q3 2024, for an estimated $45,194,203
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 2,319,877 shares (+100.2%) to their portfolio in Q3 2024, for an estimated $32,988,650
- MACQUARIE GROUP LTD removed 1,045,547 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $14,867,678
- MILLENNIUM MANAGEMENT LLC removed 939,545 shares (-21.6%) from their portfolio in Q3 2024, for an estimated $13,360,329
- GOLDMAN SACHS GROUP INC added 843,350 shares (+22.7%) to their portfolio in Q3 2024, for an estimated $11,992,437
- BRANDES INVESTMENT PARTNERS, LP added 596,577 shares (+22.6%) to their portfolio in Q3 2024, for an estimated $8,483,324
- KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC removed 585,734 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $8,329,137
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
